OUR TECHNOLOGY
Targeting the Wiskott-Aldrich-Syndrome Protein
BIMINI’s approach is based on proprietary technology that targets the Wiskott-Aldrich-Syndrome Protein (WASp), an actin nucleation related protein expressed exclusively in hematopoietic cells. WASP modulation has shown to deliver a potent anti-cancer effect. We have a proprietary portfolio of:
WASP activation
BM-011, a WASP activator, is based on the pioneering research of the Institute Oncology Research (IOR) in Switzerland.
WASP inhibition
BM-013, a WASP inhibitor.
BM-011 for Lymphomas
WASP activation has shown to promising results in difficult to treat non-Hodgkin lymphomas.
BM-013 for Leukemias
WASP inhibition has shown promising results in difficult to treat leukemias.
Our Team
BIMINI Biotech combines young ambitious entrepreneurs with scientific key-opinion-leaders and seasoned business experts
Digvijay Gahtory PhD
CEO
Maurits van den Nieuwboer PhD
COO
Stephen Croke PhD
Lead R&D Scientist
Prof. Francesco Bertoni PhD
Scientific advisor
Henk Viëtor PhD, MD
Advisor BD
Prof. Marc Peeters PhD
Advisor Clinical
Peter Maas
Advisor MedChem
Carine van den Brink
Advisor Legal
Prof. Ger Strous PhD
Advisor Cell Biology
Ernst Elhorst
Advisor Licensing
Latest News
Keep up to date with the latests progression and achievement of BIMINI Biotech.
BIMINI Biotech’s MIT Feasibility grant AUTO-WASP awarded
BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In[…]
Read more
BIMINI Biotech closes new seed round with Libertatis Ergo Holding for the development of first-in-class therapeutics
Leiden, 29 June 2023 – BIMINI Biotech, an innovative Leiden-based therapeutics start-up that develops novel therapeutics for hematological cancers, raised an additional investment of €250,000 from lead investor Libertatis Ergo[…]
Read more
Eurostars project HEMATO-WASP awarded
Leiden, 1 April 2023 – BIMINI Biotech, an innovative therapeutics startup, was recently awarded a Eureka Eurostars project with the aim of developing novel therapeutics for lymphomas. This project named[…]
Read moreContact us
Please contact us at info@biminibiotech.nl
De contactformulier wordt hier getoond. Voor het activeren moet je de parameter ”shortcode contactformulier” instellen van het Aanpassing menu.